307 related articles for article (PubMed ID: 18468682)
1. Acute myeloid leukemia and myelodysplastic syndrome following breast cancer: increased frequency of other cancers and of cancers in multiple family members.
Padmanabhan A; Baker JA; Zirpoli G; Sait SN; Ford LA; Moysich KB; Baer MR
Leuk Res; 2008 Dec; 32(12):1820-3. PubMed ID: 18468682
[TBL] [Abstract][Full Text] [Related]
2. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
3. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
[TBL] [Abstract][Full Text] [Related]
4. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk.
Patt DA; Duan Z; Fang S; Hortobagyi GN; Giordano SH
J Clin Oncol; 2007 Sep; 25(25):3871-6. PubMed ID: 17664457
[TBL] [Abstract][Full Text] [Related]
5. Leukemia incidence following primary breast carcinoma treatment.
Kaplan HG; Malmgren JA; Atwood M
Cancer; 2004 Oct; 101(7):1529-36. PubMed ID: 15378478
[TBL] [Abstract][Full Text] [Related]
6. Risk of myelodysplastic syndrome and acute myeloid leukemia post radiation treatment for breast cancer: a population-based study.
Kaplan H; Malmgren J; De Roos AJ
Breast Cancer Res Treat; 2013 Feb; 137(3):863-7. PubMed ID: 23274844
[TBL] [Abstract][Full Text] [Related]
7. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.
Praga C; Bergh J; Bliss J; Bonneterre J; Cesana B; Coombes RC; Fargeot P; Folin A; Fumoleau P; Giuliani R; Kerbrat P; Hery M; Nilsson J; Onida F; Piccart M; Shepherd L; Therasse P; Wils J; Rogers D
J Clin Oncol; 2005 Jun; 23(18):4179-91. PubMed ID: 15961765
[TBL] [Abstract][Full Text] [Related]
8. Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma.
Saso R; Kulkarni S; Mitchell P; Treleaven J; Swansbury GJ; Mehta J; Powles R; Ashley S; Kuan A; Powles T
Br J Cancer; 2000 Jul; 83(1):91-4. PubMed ID: 10883674
[TBL] [Abstract][Full Text] [Related]
9. Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors.
Kaplan HG; Malmgren JA; Li CI; Calip GS
Breast Cancer Res Treat; 2013 Dec; 142(3):629-36. PubMed ID: 24265034
[TBL] [Abstract][Full Text] [Related]
10. Incidence and susceptibility to therapy-related myeloid neoplasms.
Leone G; Fianchi L; Pagano L; Voso MT
Chem Biol Interact; 2010 Mar; 184(1-2):39-45. PubMed ID: 20026017
[TBL] [Abstract][Full Text] [Related]
11. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
Tebbi CK; London WB; Friedman D; Villaluna D; De Alarcon PA; Constine LS; Mendenhall NP; Sposto R; Chauvenet A; Schwartz CL
J Clin Oncol; 2007 Feb; 25(5):493-500. PubMed ID: 17290056
[TBL] [Abstract][Full Text] [Related]
12. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature.
Swolin B; Rödjer S; Westin J
Ann Hematol; 2008 Jun; 87(6):467-74. PubMed ID: 18351338
[TBL] [Abstract][Full Text] [Related]
13. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).
Freedman RA; Seisler DK; Foster JC; Sloan JA; Lafky JM; Kimmick GG; Hurria A; Cohen HJ; Winer EP; Hudis CA; Partridge AH; Carey LA; Jatoi A; Klepin HD; Citron M; Berry DA; Shulman LN; Buzdar AU; Suman VJ; Muss HB
Breast Cancer Res Treat; 2017 Jan; 161(2):363-373. PubMed ID: 27866278
[TBL] [Abstract][Full Text] [Related]
14. Re: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Warren JL; Brown ML
J Natl Cancer Inst; 2007 Jul; 99(13):1050; author reply 1051-2. PubMed ID: 17596580
[No Abstract] [Full Text] [Related]
15. Re: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Clavarezza M; Del Mastro L; Pronzato P; Bruzzi P; Venturini M
J Natl Cancer Inst; 2007 Jul; 99(13):1050-1; author reply 1051-2. PubMed ID: 17596581
[No Abstract] [Full Text] [Related]
16. Is family history of breast cancer a marker of susceptibility to exposures in the incidence of de novo adult acute leukemia?
Rauscher GH; Sandler DP; Poole C; Pankow J; Shore D; Bloomfield CD; Olshan AF
Cancer Epidemiol Biomarkers Prev; 2003 Apr; 12(4):289-94. PubMed ID: 12692102
[TBL] [Abstract][Full Text] [Related]
17. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
[TBL] [Abstract][Full Text] [Related]
18. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
Shenolikar R; Durden E; Meyer N; Lenhart G; Moore K
Gynecol Oncol; 2018 Nov; 151(2):190-195. PubMed ID: 30268525
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer.
Calip GS; Malmgren JA; Lee WJ; Schwartz SM; Kaplan HG
Breast Cancer Res Treat; 2015 Nov; 154(1):133-43. PubMed ID: 26450505
[TBL] [Abstract][Full Text] [Related]
20. Why is there so much therapy-related AML and MDS and so little therapy-related CML?
Gale RP; Hlatky L; Sachs RK; Radivoyevitch T
Leuk Res; 2014 Oct; 38(10):1162-4. PubMed ID: 25175829
[No Abstract] [Full Text] [Related]
[Next] [New Search]
